Dose-escalation studies expand the therapeutic and commercial potential of Hamlet Pharma’s drug candidate Alpha1H

Dose-escalation studies have been successful in mice with bladder cancer defining an optimal dose window for Alpha1H.

Thetherapeutic effect of Alpha1H increased with higher dosesand at the highest treatment dose, visible tumor tissue was no longer detected.  

Importantly, there was no toxicity even at the highest dose, confirming that Alpha1H can be both therapeutic and selective for the tumor, unlike many current cancer therapies 

These findings open up novel possibilities to permanently remove cancer by adjusting the dose of Alpha1H administered to specific tumors and tissue sites and to tailor treatment protocols to fit individual patients. Optimizing the dose is essential to achieve the best treatment effect. 

Based on these findings, Hamlet Pharma now seeks regulatory approval for dose-escalation studies in patients with bladder cancer.  

For more information, please contact

Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46 709 42 65 49

catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57

mats.persson@hamletpharma.com 

HAMLET Pharma, listed on Spotlight Stock Market, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses on drugs, which will be used primarily for the treatment and prevention of cancer. HAMLET kills tumour cells, and has proven safe in proof-of-concept studies in animal models. HAMLET has shown a therapeutic effect on skin papillomas in a placebo-controlled clinical trial and injection of HAMLET into the bladders of patients with bladder cancer has caused the shedding of dead cancer cells. A phase I/II clinical trial in human patients with bladder cancer is currently ongoing. HAMLET is a registered trademark of HAMLET Pharma.


Subscribe

Documents & Links